Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded in type 2 diabetes and obesity. Marking the four ...

The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.

Devonian Health Group has received authorisation from Health Canada for its CTA to begin a Phase II/III study of Thykamine cream to treat mild-to-moderate atopic dermatitis in paediatric patients.

The Phase III trial failed to meet its co-primary endpoints or any of its key secondary endpoints. Credit: Ton Photographer 4289 / Shuttertock.com Kolon TissueGene’s stock has dropped after a Phase ...

The pre-screening process uses AI to analyse patient profiles and identify possible matches for trials before full review. Credit: metamorworks / Shutterstock.com. Massive Bio has partnered with FOMAT ...

Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to a pivotal study now set. The Phase II (J201; ...

Bayer and Henry Ford Health intend to work together throughout clinical trials. Credit: Stock-Asso / Shutterstock.com. Bayer and Henry Ford Health have entered a strategic research partnership aimed ...

GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.

Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.